New Schering chief has plans for imaging agents:
This article was originally published in Clinica
Executive Summary
The incoming chairman of the executive board at German company Schering pharmaceuticals company promised that it would leverage its brand leading position in radiopharmaceuticals. Dr Hubertus Erlen takes over from Dr Giuseppe Vita, who retires after 12 years as chairman. Schering's R&D strategy is to use carrier molecules used in diagnostic imaging to destroy cancer cells.